Triple-Drug cocktail aims to boost ovarian cancer surgery success

NCT ID NCT07667751

Recruiting now Disease control Sponsor: Bai-Rong Xia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of three drugs—ipalotinib, sunitinib, and olaparib—given before surgery to people with a specific type of advanced ovarian cancer (HRD-positive). The goal is to shrink tumors enough to allow complete removal during surgery. The study will enroll 35 participants and track how many achieve complete tumor removal, as well as safety and response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ipalotinib (Tislelizumab), sunitinib, and olaparib
What this could lead to: If successful, this combination could improve the rate of complete tumor removal during surgery for advanced ovarian cancer, potentially leading to better outcomes.
What could go wrong: This is a small, early-phase study with only 35 participants and no comparison group. The drug combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARY CANCER

Contacts and locations

Locations

Anhui Cancer Hospital
RECRUITING

Hefei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.